Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANI PHARMACEUTICALS INC Director's Dealing 2018

Mar 15, 2018

31676_dirs_2018-03-14_66e0952d-0ecd-4625-beb9-f6f5aaf85ca8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANI PHARMACEUTICALS INC (ANIP)
CIK: 0001023024
Period of Report: 2018-03-12

Reporting Person: PRZYBYL ARTHUR (Director, President and CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-03-12 Common Stock M 15723 $6.36 Acquired 225706 Direct
2018-03-13 Common Stock S 23475 $61.52 Disposed 202231 Direct
2018-03-13 Common Stock S 6525 $62.63 Disposed 195706 Direct
2018-03-14 Common Stock S 10000 $62.03 Disposed 185706 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-03-12 Stock Option $6.36 M 15723 Disposed 2023-07-11 Common Stock (15723) Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $61.11 to $62.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: This transaction was executed in multiple trades at prices ranging from $62.12 to $63.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $62.00 to $62.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was July 12, 2013.